Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CRP

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,551 result(s) found for: CRP. Displaying page 68 of 78.
    EudraCT Number: 2007-005759-41 Sponsor Protocol Number: WA20496 Start Date*: 2008-03-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004331-39 Sponsor Protocol Number: INDOOR Start Date*: 2015-01-02
    Sponsor Name:Fundació Vall Hebron Institut de Recerca
    Full Title: HIV Reservoir Dynamics After Switching To Dolutegravir in Patients on a PI/r Based Regimen. A Phase IV Open Randomized Trial
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020423-51 Sponsor Protocol Number: ETA0881X1-4718 Start Date*: 2011-02-17
    Sponsor Name:Asklepios Klinik Sankt Augustin
    Full Title: Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
    Medical condition: Active enthesitis-related arthrtitis as a category of juvenile idiopathic arthritis (ERA-JIA) as determined by International League of Associations for Rheumatology (ILAR) criteria.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005288-86 Sponsor Protocol Number: C87077 Start Date*: 2009-03-18
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotr...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000515-15 Sponsor Protocol Number: C LF0242780-01 05 04 Start Date*: 2007-01-30
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monoth...
    Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg pravastatin alone.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005449-19 Sponsor Protocol Number: Start Date*: 2013-04-24
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A double-blind, randomised controlled trial of percutaneous transluminal angioplasty (PTA) & Ramipril versus PTA & placebo in the management of intermittent claudication (IC)
    Medical condition: Peripheral Arterial Disease: Intermittent Claudication
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10009241 Claudication intermittent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002896-40 Sponsor Protocol Number: B3281001 Start Date*: 2012-08-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGR...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004354-15 Sponsor Protocol Number: DANPAPP Start Date*: 2017-12-13
    Sponsor Name: Rigshospitalet
    Full Title: Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study ...
    Medical condition: Psoriasis and psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020872-49 Sponsor Protocol Number: PI10-Pr.CHOUKROUN-FRENCH Start Date*: 2013-04-18
    Sponsor Name:CHU Amiens
    Full Title: Étude randomisée, en double aveugle, versus placebo, évaluant chez des patients porteurs d'une MRC, non dialysés, l'effet du traitement par carbonate de sevelamer sur le contrôle des taux sériques ...
    Medical condition: Maladies Rénales Chroniques au stade 3b et 4 (DFG compris entre 15 et 45 ml/min)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004545-32 Sponsor Protocol Number: EP-002 Start Date*: 2020-04-16
    Sponsor Name:Empros Pharma AB
    Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005370-62 Sponsor Protocol Number: ANAKIN-RA-DIABETES Start Date*: 2013-02-18
    Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
    Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe...
    Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037740 RA LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001748-24 Sponsor Protocol Number: ImmCoVA Start Date*: 2020-05-15
    Sponsor Name:Karolinska University Hospital
    Full Title: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treat...
    Medical condition: COVID-19 infection in patients with respiratory distress.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000699-32 Sponsor Protocol Number: EU-0208/REMICADEPSO1006 Start Date*: 2011-09-28
    Sponsor Name:UZ KULeuven, service of Rheumatology
    Full Title: Nail involvement in psoriatic arthritis: a cross-sectional and observational prospective study.
    Medical condition: psoriatic artritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000684-33 Sponsor Protocol Number: OC5-DB-02 Start Date*: 2017-06-06
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001880-22 Sponsor Protocol Number: PP-CT02 Start Date*: 2018-08-23
    Sponsor Name:PILA PHARMA AB
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients w...
    Medical condition: Diabetes Type II
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002130-33 Sponsor Protocol Number: ZILU-COV Start Date*: 2020-05-26
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COV...
    Medical condition: COVID-19 patients with acute hypoxic respiratory failure.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000598-95 Sponsor Protocol Number: HS-20-674 Start Date*: 2021-07-30
    Sponsor Name:Camurus AB
    Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ...
    Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004826-27 Sponsor Protocol Number: GI1863 Start Date*: 2019-04-11
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advance...
    Medical condition: First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease.
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008596 Cholangiocarcinoma recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074878 Hilar cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074879 Extrahepatic cholangiocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002023-28 Sponsor Protocol Number: N/2015/70 Start Date*: 2018-06-04
    Sponsor Name:CHU Besançon
    Full Title: Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period
    Medical condition: Transplanté rénal à haut risque de développer un diabète de novo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002028-19 Sponsor Protocol Number: RH-CARD-Pharma001 Start Date*: 2022-02-01
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet
    Full Title: Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development – a 2x2 multifactorial, double-blinded, randomized, ...
    Medical condition: Acute Myocardial Infarction with increased risk of Cardiogenic Shock.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 07:55:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA